836例非梗阻性无精子症患者外显子组测序的可操作次要发现及其在患者管理中的价值
该回顾性队列研究对6国10家诊所836例非梗阻性无精子症(NOA)患者的外显子组测序数据进行分析,评估85个推荐基因中的次要发现(SFs)。结果显示SFs总频率为3.6%,其中ACMG SF v2.0基因占3.3%;每70例中1例携带家族性癌症综合征相关基因变异,每60例中1例易感先天性心脏病或其他心血管疾病。37%(11/30)携带SFs的患者其变异位于小鼠雄性不育相关基因,提示部分SFs可能与精子发生障碍共 contributory。
要点
- NOA患者中可操作的次要发现频率为3.6%,ACMG SF v2.0基因占3.3%。
- 每70例NOA患者中1例携带家族性癌症综合征相关基因的次要发现。
- 每60例NOA患者中1例易感先天性心脏病或其他心血管疾病。
核心结论
- 每28例NOA病例中1例携带可识别的、医学上可操作的次要发现。
- 37%(11/30)携带SFs的患者其变异位于小鼠雄性不育相关基因,提示部分SFs可能对精子发生障碍有共 contributory 作用。
- 需进一步研究以确定这些观察是偶然发现还是NOA患者的SFs谱确实与一般人群不同。
研究设计与样本
- 回顾性队列研究,患者来自6个国家10家诊所,为国际GEMINI研究框架的一部分。
- 分析836例NOA患者的外显子组测序数据,评估85个推荐基因中的次要发现。
- 85个基因来自美国医学遗传学与基因组学学会(ACMG)、Geisinger的MyCode和Clinical Genome Resource的推荐。
主要发现
- SFs总频率为3.6%,其中ACMG SF v2.0的59个基因中频率为3.3%。
- 每70例患者中1例携带与家族性癌症综合征相关基因的SFs。
- 每60例患者中1例易感先天性心脏病或其他心血管疾病。
- 37%(11/30)携带SFs的患者其变异位于小鼠雄性不育相关基因。
- 回顾性评估在数例中确认了临床-分子诊断。
临床怎么用
- 随着外显子组测序纳入常规男科实践以进行分子诊断,额外评估SFs可告知不育患者未来重大健康问题。
- 及时检测SFs并进行相应遗传咨询将拓宽疾病预防和早期治疗的选择,并为家庭计划的选择和机会提供信息。
局限性
- 队列中非白种人比例较低(9%)。
- 由于并非所有携带SFs的男性均有全面的回顾性临床数据,无法确认临床-分子诊断并评估特定变异的 penetrance。
- 需进一步研究以确定这些观察是偶然发现还是NOA患者的SFs谱确实与一般人群不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the load, distribution and added clinical value of secondary findings (SFs) identified in exome sequencing (ES) of patients with non-obstructive azoospermia (NOA)? SUMMARY ANSWER: One in 28 NOA cases carried an identifiable, medically actionable SF. WHAT IS KNOWN ALREADY: In addition to molecular diagnostics, ES allows assessment of clinically actionable disease-related gene variants that are not connected to the patient's primary diagnosis, but the knowledge of which may allow the prevention, delay or amelioration of late-onset monogenic conditions. Data on SFs in specific clinical patient groups, including reproductive failure, are currently limited. STUDY DESIGN, SIZE, DURATION: The study group was a retrospective cohort of patients with NOA recruited in 10 clinics across six countries and formed in the framework of the international GEMINI (The GEnetics of Male INfertility Initiative) study. PARTICIPANTS/MATERIALS, SETTING, METHODS: ES data of 836 patients with NOA were exploited to analyze SFs in 85 genes recommended by the American College of Medical Genetics and Genomics (ACMG), Geisinger's MyCode, and Clinical Genome Resource. The identified 6374 exonic variants were annotated with ANNOVAR and filtered for allele frequency, retaining 1381 rare or novel missense and loss-of-function variants. After automatic assessment of pathogenicity with ClinVar and InterVar, 87 variants were manually curated. The final list of confident disease-causing SFs was communicated to the corresponding GEMINI centers. When patient consent had been given, available family health history and non-andrological medical data were retrospectively assessed. MAIN RESULTS AND THE ROLE OF CHANCE: We found a 3.6% total frequency of SFs, 3.3% from the 59 ACMG SF v2.0 genes. One in 70 patients carried SFs in genes linked to familial cancer syndromes, whereas 1 in 60 cases was predisposed to congenital heart disease or other cardiovascular conditions. Retrospective assessment confirmed clinico-molecular diagnoses in several cases. Notably, 37% (11/30) of patients with SFs carried variants in genes linked to male infertility in mice, suggesting that some SFs may have a co-contributing role in spermatogenic impairment. Further studies are needed to determine whether these observations represent chance findings or the profile of SFs in NOA patients is indeed different from the general population. LIMITATIONS, REASONS FOR CAUTION: One limitation of our cohort was the low proportion of non-Caucasian ethnicities (9%). Additionally, as comprehensive clinical data were not available retrospectively for all men with SFs, we were not able to confirm a clinico-molecular diagnosis and assess the penetrance of the specific variants. WIDER IMPLICATIONS OF THE FINDINGS: For the first time, this study analyzed medically actionable SFs in men with spermatogenic failure. With the evolving process to incorporate ES into routine andrology practice for molecular diagnostic purposes, additional assessment of SFs can inform about future significant health concerns for infertility patients. Timely detection of SFs and respective genetic counseling will broaden options for disease prevention and early treatment, as well as inform choices and opportunities regarding family planning. A notable fraction of SFs was detected in genes implicated in maintaining genome integrity, essential in both mitosis and meiosis. Thus, potential genetic pleiotropy may exist between certain adult-onset monogenic diseases and NOA. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Estonian Research Council grants IUT34-12 and PRG1021 (M.L. and M.P.); National Institutes of Health of the United States of America grant R01HD078641 (D.F.C., K.I.A. and P.N.S.); National Institutes of Health of the United States of America grant P50HD096723 (D.F.C. and P.N.S.); National Health and Medical Research Council of Australia grant APP1120356 (M.K.O'B., D.F.C. and K.I.A.); Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Inovação grant POCI-01-0145-FEDER-007274 (A.M.L., F.C. and J.G.) and FCT: IF/01262/2014 (A.M.L.). J.G. was partially funded by FCT/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES), through the Centre for Toxicogenomics and Human Health-ToxOmics (grants UID/BIM/00009/2016 and UIDB/00009/2020). M.L.E. is a consultant for, and holds stock in, Roman, Sandstone, Dadi, Hannah, Underdog and has received funding from NIH/NICHD. Co-authors L.K., K.L., L.N., K.I.A., P.N.S., J.G., F.C., D.M.-M., K.A., K.A.J., M.K.O'B., A.M.L., D.F.C., M.P. and M.L. declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Kasak L, Lillepea K, Nagirnaja L, et al. Actionable secondary findings following exome sequencing of 836 non-obstructive azoospermia cases and their value in patient management. Hum Reprod. 2022. PMID: 35535697. doi:10.1093/humrep/deac100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。